ArticleClinical parkinsonism & related disorders2026
One patient, one destiny: A cluster analysis of the Parkinson's progression Markers Initiative (PPMI) cohort.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is characterized by heterogeneity. While previous efforts have aimed to categorize patients by clinical subtypes, these classifications have not reliably predicted outcomes, underscoring the complexity and variability of disease progression. Methods: Using data from the Parkinson's Progression Markers Initiative (PPMI), we conducted a longitudinal analysis of 209 individuals with PD over five years. We used cluster analysis to identify trajectory clusters in the progression of motor symptoms. Participants were categorized based on baseline variables, including age, sex, race, BMI, genetic mutation status, medical history, presence of jaw and limb tremors, and alpha-synuclein seeding status. Motor and non-motor outcomes, such as gait abnormalities, dyskinesia, motor fluctuations, dystonia, cognitive impairment, hallucinations, and others, were evaluated, along with the progression of the levodopa equivalent daily dose (LEDD). Sankey plots illustrated patient trajectories from baseline to outcome groups over time. Results: Trajectory cluster analysis of MDS-UPDRS Part III scores identified three progression patterns: slow, intermediate, and rapid, with higher baseline BMI associated with faster motor progression (P < 0.01). Grouping based on baseline features identified 136 distinct patient groups, with substantial dispersion across clinical outcomes. Patients with identical baseline profiles frequently diverged into separate outcome groups. Genetic/SAA stratification also showed marked variability in progression with no significant association across trajectory clusters (P > 0.05). Conclusion: These findings highlight the existence of highly individualized clinical trajectories, even among patients with similar baseline characteristics, within the specific set of baseline variables examined in this study. This emphasizes the need for a personalized, patient-centered approach in both the management and study of Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.